171 related articles for article (PubMed ID: 29476572)
1. Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe.
Cacoub P; Buggisch P; Carrión JA; Cooke GS; Zignego AL; Beckerman R; Younossi Z
J Viral Hepat; 2018 Jul; 25(7):811-817. PubMed ID: 29476572
[TBL] [Abstract][Full Text] [Related]
2. Direct medical costs associated with the extrahepatic manifestations of hepatitis C virus infection in France.
Cacoub P; Vautier M; Desbois AC; Saadoun D; Younossi Z
Aliment Pharmacol Ther; 2018 Jan; 47(1):123-128. PubMed ID: 29044584
[TBL] [Abstract][Full Text] [Related]
3. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.
Younossi Z; Park H; Henry L; Adeyemi A; Stepanova M
Gastroenterology; 2016 Jun; 150(7):1599-1608. PubMed ID: 26924097
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
5. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
Roebuck MC; Liberman JN
Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
[TBL] [Abstract][Full Text] [Related]
7. Cost of depression in Europe.
Sobocki P; Jönsson B; Angst J; Rehnberg C
J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
[TBL] [Abstract][Full Text] [Related]
8. Extrahepatic manifestations of HCV: the role of direct acting antivirals.
Polo ML; Laufer N
Expert Rev Anti Infect Ther; 2017 Aug; 15(8):737-746. PubMed ID: 28696154
[TBL] [Abstract][Full Text] [Related]
9. The economic burden of HCV-induced diseases in Italy. A probabilistic cost of illness model.
Marcellusi A; Viti R; Capone A; Mennini FS
Eur Rev Med Pharmacol Sci; 2015; 19(9):1610-20. PubMed ID: 26004601
[TBL] [Abstract][Full Text] [Related]
10. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015.
Lu CY; Zhang F; Golonski N; Lupton C; Jeffrey P; Wagner AK
Value Health; 2018 Jun; 21(6):692-697. PubMed ID: 29909874
[TBL] [Abstract][Full Text] [Related]
11. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
12. Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection.
Retamozo S; Brito-Zerón P; Quartuccio L; De Vita S; Ramos-Casals M
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1085-1101. PubMed ID: 28715943
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.
Ahmed A; Gonzalez SA; Cholankeril G; Perumpail RB; McGinnis J; Saab S; Beckerman R; Younossi ZM
Hepatology; 2017 Jul; 66(1):46-56. PubMed ID: 28257591
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era.
Cacoub P; Vautier M; Desbois AC; Lafuma A; Saadoun D
Liver Int; 2017 Dec; 37(12):1805-1813. PubMed ID: 28467688
[TBL] [Abstract][Full Text] [Related]
15. Real-world economic burden of hepatitis C and impact of direct-acting antivirals in France: A nationwide claims data analysis.
Lam L; Carrieri P; Hejblum G; Bellet J; Bourlière M; Carrat F
Liver Int; 2024 May; 44(5):1233-1242. PubMed ID: 38375961
[TBL] [Abstract][Full Text] [Related]
16. Effect of treating chronic hepatitis C with direct-acting antivirals on extrahepatic cutaneous manifestations.
El Kassas M; Hegazy OM; Salah EM
World J Hepatol; 2020 Oct; 12(10):841-849. PubMed ID: 33200021
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
Rattay T; Dumont IP; Heinzow HS; Hutton DW
Gastroenterology; 2017 Dec; 153(6):1531-1543.e2. PubMed ID: 29074450
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.
Lafuma A; Brézin A; Lopatriello S; Hieke K; Hutchinson J; Mimaud V; Berdeaux G
Pharmacoeconomics; 2006; 24(2):193-205. PubMed ID: 16460138
[TBL] [Abstract][Full Text] [Related]
19. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas.
El Khoury AC; Wallace C; Klimack WK; Razavi H
J Med Econ; 2012; 15(5):887-96. PubMed ID: 22458755
[TBL] [Abstract][Full Text] [Related]
20. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients.
Soriano V; Berenguer J
Curr Opin HIV AIDS; 2015 Sep; 10(5):309-15. PubMed ID: 26132342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
